Search Results - "WINICK, Naomi J"

Improved Survival for Children and Adolescents With Acute Lymphoblastic Leukemia Between 1990 and 2005: A Report From the Children's Oncology Group by HUNGER, Stephen P, XIAOMIN LU, DEVIDAS, Meenakshi, CAMITTA, Bruce M, GAYNON, Paul S, WINICK, Naomi J, REAMAN, Gregory H, CARROLL, William L

“…To examine population-based improvements in survival and the impact of clinical covariates on outcome among children and adolescents with acute lymphoblastic…”
Get full text

Impact of Asparaginase Discontinuation on Outcome in Childhood Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group by Gupta, Sumit, Wang, Cindy, Raetz, Elizabeth A, Schore, Reuven, Salzer, Wanda L, Larsen, Eric C, Maloney, Kelly W, Mattano, Jr, Len A, Carroll, William L, Winick, Naomi J, Hunger, Stephen P, Loh, Mignon L, Devidas, Meenakshi

“…Asparaginase (ASNase) is an important component of acute lymphoblastic leukemia (ALL) treatment, but is often discontinued because of toxicity. ASNase ( )…”
Get full text

Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children's Oncology Group study AALL0232 by Borowitz, Michael J., Wood, Brent L., Devidas, Meenakshi, Loh, Mignon L., Raetz, Elizabeth A., Salzer, Wanda L., Nachman, James B., Carroll, Andrew J., Heerema, Nyla A., Gastier-Foster, Julie M., Willman, Cheryl L., Dai, Yunfeng, Winick, Naomi J., Hunger, Stephen P., Carroll, William L., Larsen, Eric

“…Minimal residual disease (MRD) is highly prognostic in pediatric B-precursor acute lymphoblastic leukemia (B-ALL). In Children's Oncology Group high-risk B-ALL…”
Get full text

FLT3 inhibitor lestaurtinib plus chemotherapy for newly diagnosed KMT2A-rearranged infant acute lymphoblastic leukemia: Children’s Oncology Group trial AALL0631 by Brown, Patrick A., Kairalla, John A., Hilden, Joanne M., Dreyer, ZoAnn E., Carroll, Andrew J., Heerema, Nyla A., Wang, Cindy, Devidas, Meenakshi, Gore, Lia, Salzer, Wanda L., Winick, Naomi J., Carroll, William L., Raetz, Elizabeth A., Borowitz, Michael J., Small, Donald, Loh, Mignon L., Hunger, Stephen P.

“…Infants with KMT2A ‐rearranged acute lymphoblastic leukemia ( KMT2A -r ALL) have a poor prognosis. KMT2A -r ALL overexpresses FLT3, and the FLT3 inhibitor…”
Get full text

Genome-wide study of methotrexate clearance replicates SLCO1B1 by Ramsey, Laura B., Panetta, John C., Smith, Colton, Yang, Wenjian, Fan, Yiping, Winick, Naomi J., Martin, Paul L., Cheng, Cheng, Devidas, Meenakshi, Pui, Ching-Hon, Evans, William E., Hunger, Stephen P., Loh, Mignon, Relling, Mary V.

“…Methotrexate clearance can influence the cure of and toxicity in children with acute lymphoblastic leukemia (ALL). We estimated methotrexate plasma clearance…”
Get full text

Outcomes after late bone marrow and very early central nervous system relapse of childhood B-acute lymphoblastic leukemia: a report from the Children's Oncology Group phase III study AALL0433 by Lew, Glen, Chen, Yichen, Lu, Xiaomin, Rheingold, Susan R, Whitlock, James A, Devidas, Meenakshi, Hastings, Caroline A, Winick, Naomi J, Carroll, William L, Wood, Brent L, Borowitz, Michael J, Pulsipher, Michael A, Hunger, Stephen P

“…Outcomes after relapse of childhood B-acute lymphoblastic leukemia (B-ALL) are poor, and optimal therapy is unclear. Children's Oncology Group study AALL0433…”
Get full text

Novel Susceptibility Variants at 10p12.31-12.2 for Childhood Acute Lymphoblastic Leukemia in Ethnically Diverse Populations by HENG XU, WENJIAN YANG, HUNTSMAN, Scott, TORGERSON, Dara G, DEAN, Michael, WINICK, Naomi J, MARTIN, Paul L, CAMITTA, Bruce M, BOWMAN, W. Paul, WILLMAN, Cheryl L, CARROLL, William L, MULLIGHAN, Charles G, PEREZ-ANDREU, Virginia, BHOJWANI, Deepa, HUNGER, Stephen P, PUI, Ching-Hon, EVANS, William E, RELLING, Mary V, LOH, Mignon L, YANG, Jun J, DEVIDAS, Meenakshi, YIPING FAN, CHENG CHENG, DEQING PEI, SCHEET, Paul, BURCHARD, Esteban González, ENG, Celeste

“…Acute lymphoblastic leukemia (ALL) is the most common cancer in children and the incidence of ALL varies by ethnicity. Although accumulating evidence indicates…”
Get full text

Outcomes in adolescent and young adult patients (16 to 30 years) compared to younger patients treated for high-risk B-lymphoblastic leukemia: report from Children’s Oncology Group Study AALL0232 by Burke, Michael J., Devidas, Meenakshi, Chen, Zhiguo, Salzer, Wanda L., Raetz, Elizabeth A., Rabin, Karen R., Heerema, Nyla A., Carroll, Andrew J., Gastier-Foster, Julie M., Borowitz, Michael J., Wood, Brent L., Winick, Naomi J., Carroll, William L., Hunger, Stephen P., Loh, Mignon L., Larsen, Eric C.

“…Adolescent and young adult (AYA) patients 16–30 years old with high-risk acute lymphoblastic leukemia (HR-ALL) have inferior outcomes compared to younger…”
Get full text

Intrachromosomal Amplification of Chromosome 21 Is Associated With Inferior Outcomes in Children With Acute Lymphoblastic Leukemia Treated in Contemporary Standard-Risk Children's Oncology Group Studies: A Report From the Children's Oncology Group by HEEREMA, Nyla A, CARROLL, Andrew J, WOOD, Brent L, WINICK, Naomi J, CARROLL, William L, HUNGER, Stephen P, RAETZ, Elizabeth A, DEVIDAS, Meenakshi, LOH, Mignon L, BOROWITZ, Michael J, GASTIER-FOSTER, Julie M, LARSEN, Eric C, MATTANO, Leonard A, MOLONEY, Kelly W, WILLMAN, Cheryl L

“…Five-year overall survival (OS) for children with B-cell precursor acute lymphoblastic leukemia (B-ALL) exceeds 90% with risk-adapted therapy. Age, initial WBC…”
Get full text

Circulating microRNAs: Potential Markers of Cardiotoxicity in Children and Young Adults Treated With Anthracycline Chemotherapy by Leger, Kasey J, Leonard, David, Nielson, Danelle, de Lemos, James A, Mammen, Pradeep P A, Winick, Naomi J

“…Biomarkers for early detection of anthracycline (AC)-induced cardiotoxicity may allow cardioprotective intervention before irreversible damage. Circulating…”
Get full text

ARID5B Genetic Polymorphisms Contribute to Racial Disparities in the Incidence and Treatment Outcome of Childhood Acute Lymphoblastic Leukemia by HENG XU, CHENG CHENG, ENG, Celeste, DEAN, Michael, ANTILLON, Frederico, WINICK, Naomi J, MARTIN, Paul L, WILLMAN, Cheryl L, CAMITTA, Bruce M, REAMAN, Gregory H, CARROLL, William L, LOH, Mignon, DEVIDAS, Meenakshi, EVANS, William E, PUI, Ching-Hon, HUNGER, Stephen P, RELLING, Mary V, YANG, Jun J, DEQING PEI, YIPING FAN, WENJIAN YANG, NEALE, Geoff, SCHEET, Paul, BURCHARD, Esteban G, TORGERSON, Dara G

“…Recent genome-wide screens have identified genetic variations in ARID5B associated with susceptibility to childhood acute lymphoblastic leukemia (ALL). We…”
Get full text

Favorable Trisomies and ETV6-RUNX1 Predict Cure in Low-Risk B-Cell Acute Lymphoblastic Leukemia: Results From Children's Oncology Group Trial AALL0331 by Mattano, Jr, Leonard A, Devidas, Meenakshi, Maloney, Kelly W, Wang, Cindy, Friedmann, Alison M, Buckley, Patrick, Borowitz, Michael J, Carroll, Andrew J, Gastier-Foster, Julie M, Heerema, Nyla A, Kadan-Lottick, Nina S, Matloub, Yousif H, Marshall, David T, Stork, Linda C, Loh, Mignon L, Raetz, Elizabeth A, Wood, Brent L, Hunger, Stephen P, Carroll, William L, Winick, Naomi J

“…Children's Oncology Group (COG) AALL0331 tested whether pegaspargase intensification on a low-intensity chemotherapy backbone would improve the continuous…”
Get full text

Outstanding outcomes with two low intensity regimens in children with low-risk B-ALL: a report from COG AALL0932 by Schore, Reuven J., Angiolillo, Anne L., Kairalla, John A., Devidas, Meenakshi, Rabin, Karen R., Zweidler-McKay, Patrick, Borowitz, Michael J., Wood, Brent, Carroll, Andrew J., Heerema, Nyla A., Relling, Mary V., Hitzler, Johann, Kadan-Lottick, Nina S., Maloney, Kelly, Wang, Cindy, Carroll, William L., Winick, Naomi J., Raetz, Elizabeth A., Loh, Mignon L., Hunger, Stephen P.

Get full text

Outstanding outcomes in infants with KMT2A -germline acute lymphoblastic leukemia treated with chemotherapy alone: results of the Children's Oncology Group AALL0631 trial by Guest, Erin M, Kairalla, John A, Hilden, Joanne M, Dreyer, ZoAnn E, Carroll, Andrew J, Heerema, Nyla A, Wang, Cindy Y, Devidas, Meenakshi, Gore, Lia, Salzer, Wanda L, Winick, Naomi J, Carroll, William L, Raetz, Elizabeth A, Borowitz, Michael, Loh, Mignon L, Hunger, Stephen P, Brown, Patrick A

Get full text

Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG) by Schultz, Kirk R., Pullen, D. Jeanette, Sather, Harland N., Shuster, Jonathan J., Devidas, Meenakshi, Borowitz, Michael J., Carroll, Andrew J., Heerema, Nyla A., Rubnitz, Jeffrey E., Loh, Mignon L., Raetz, Elizabeth A., Winick, Naomi J., Hunger, Stephen P., Carroll, William L., Gaynon, Paul S., Camitta, Bruce M.

“…The Children's Cancer Group (CCG) and the Pediatric Oncology Group (POG) joined to form the Children's Oncology Group (COG) in 2000. This merger allowed…”
Get full text

KMT2A partner genes in infant acute lymphoblastic leukemia have prognostic significance and correlate with age, white blood cell count, sex, and central nervous system involvement: a Children's Oncology Group P9407 trial study by Robinson, Blaine W, Kairalla, John A, Devidas, Meenakshi, Carroll, Andrew J, Harvey, Richard C, Heerema, Nyla A, Willman, Cheryl L, Ball, Amanda R, Woods, Elliot C, Ballantyne, Nancy C, Urtishak, Karen A, Behm, Frederick G, Reaman, Gregory H, Hilden, Joanne M, Camitta, Bruce M, Winick, Naomi J, Pullen, Jeanette, Carroll, William L, Hunger, Stephen P, Dreyer, ZoAnn E, Felix, Carolyn A

Get full text

Intensified chemotherapy without SCT in infant ALL: Results from COG P9407 (Cohort 3) by Dreyer, ZoAnn E., Hilden, Joanne M., Jones, Tamekia L., Devidas, Meenakshi, Winick, Naomi J., Willman, Cheryl L., Harvey, Richard C., Chen, I-Ming, Behm, Fred G., Pullen, Jeanette, Wood, Brent L., Carroll, Andrew J., Heerema, Nyla A., Felix, Carolyn A., Robinson, Blaine, Reaman, Gregory H., Salzer, Wanda L., Hunger, Stephen P., Carroll, William L., Camitta, Bruce M.

“…Background Infants with acute lymphoblastic leukemia (ALL) present with aggressive disease and a poor prognosis. Early relapse within 6–9 months of diagnosis…”
Get full text

The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia by Liu, Yu, Easton, John, Shao, Ying, Maciaszek, Jamie, Wang, Zhaoming, Wilkinson, Mark R, McCastlain, Kelly, Edmonson, Michael, Pounds, Stanley B, Shi, Lei, Zhou, Xin, Ma, Xiaotu, Sioson, Edgar, Li, Yongjin, Rusch, Michael, Gupta, Pankaj, Pei, Deqing, Cheng, Cheng, Smith, Malcolm A, Auvil, Jaime Guidry, Gerhard, Daniela S, Relling, Mary V, Winick, Naomi J, Carroll, Andrew J, Heerema, Nyla A, Raetz, Elizabeth, Devidas, Meenakshi, Willman, Cheryl L, Harvey, Richard C, Carroll, William L, Dunsmore, Kimberly P, Winter, Stuart S, Wood, Brent L, Sorrentino, Brian P, Downing, James R, Loh, Mignon L, Hunger, Stephen P, Zhang, Jinghui, Mullighan, Charles G

“…Charles Mullighan, Stephen Hunger, Jinghui Zhang and colleagues report a genomic analysis of 264 pediatric and young adult T-lineage acute lymphoblastic…”
Get full text

Disparities in Cancer Survival Among Adolescents and Young Adults: A Population-Based Study of 88 000 Patients by Murphy, Caitlin C, Lupo, Philip J, Roth, Michael E, Winick, Naomi J, Pruitt, Sandi L

“…Abstract Background Adolescents and young adults (AYA, aged 15-39 years) diagnosed with cancer comprise a growing, yet understudied, population. Few studies…”
Get full text

Children's Oncology Group AALL0434: A Phase III Randomized Clinical Trial Testing Nelarabine in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia by Dunsmore, Kimberly P, Winter, Stuart S, Devidas, Meenakshi, Wood, Brent L, Esiashvili, Natia, Chen, Zhiguo, Eisenberg, Nancy, Briegel, Nikki, Hayashi, Robert J, Gastier-Foster, Julie M, Carroll, Andrew J, Heerema, Nyla A, Asselin, Barbara L, Rabin, Karen R, Zweidler-Mckay, Patrick A, Raetz, Elizabeth A, Loh, Mignon L, Schultz, Kirk R, Winick, Naomi J, Carroll, William L, Hunger, Stephen P

“…Nelarabine is effective in inducing remission in patients with relapsed and refractory T-cell acute lymphoblastic leukemia (T-ALL) but has not been fully…”
Get full text